Thus, although ENA only has an FDA-approval label for R/R AML with IDH2 mutations, the NCCN guidelines provide a recommendation to consider frontline ENA use for patients older than 60 years who are not candidates for intensive remission induction [45]. This evidence concerns the gene IDH2 and acute myeloid leukemia.